|
Immunotherapy and Antifungal Drugs of Candidiasis: Achievements and Challenges
|
Leili Aghebati-Maleki    , Ali Aghebati-Maleki , Ali Fotouhi , Sanam Nami * |
| Department of Parasitology and Mycology, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran. , namis@tbzmed.ac.ir |
|
|
Abstract: (1131 Views) |
| Candida albicans is the most common cause of invasive candidiasis, but in recent years the incidence of infections caused by other species such as Candida Kruzei, Candida glabrata, Candida tropicalis, Candida parapsilosis and Candida lusitania has increased. In the last decade, the treatment methods for invasive candidiasis have changed completely, and a successful treatment depends on the timely start of treatment, the selection of an effective drug, and the lack of resistance of the fungus to that particular drug. On the other hand, the widespread use of immunosuppressive drugs as well as organ transplants has all caused widespread problems in the treatment of invasive candidiasis. Together, these observations highlight a rationale for the immediate development of new immunotherapy methods to enhance antifungal therapy in immunocompromised hosts. The past decade has seen great advances in our understanding of fungal immunobiology, leading to a number of new molecular and cellular immunotherapy methods for invasive fungal infections. Therefore, the aim of this study was to review the common and new antifungal drugs in the treatment of invasive candidiasis and to discuss the role of immunotherapy in better prevention and control of the disease. |
Article number: 1 |
| Keywords: Immunotherapy, Antifungal Drugs, Fungal Infections |
|
|
Full-Text [PDF 473 kb]
(393 Downloads)
|
Type of Study: review article |
Subject:
Immunology
Received: 2021/12/19 | Accepted: 2022/06/22 | Published: 2021/10/2
|
|
|
|
|
|
|
| Send email to the article author |
|
|
|
| Add your comments about this article |
|
|
|
.png)
.png)
